Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.
Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.
Sells disposable consumables through distributors and hospital tenders, a business of high volumes and steady repeat use. China's volume-based procurement, national bulk tenders in which the lowest bids win large orders, has pushed down prices on implants and other devices, so winning tenders matters.
In one line: China's answer to a diversified Becton Dickinson/Medtronic-lite medical device maker.
Moat: narrow (scale, regulatory licence, distribution). Broad product registrations and a large domestic distribution network across China's hospital system.
Headquarters: Weihai, Shandong, China · Founded: 1988 · Employees: 13,307
Size Shandong Weigao Group Medical Polymer (1066.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.82B, the 429th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.17 on 18 Nov 2026.
Performance Over six months the shares fell 7.7%, against +3.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 7.5% over the last twelve months (peer median +14.5%); the operating margin is 13.6% (peer median 14.6%).
Valuation It trades at 8.2× forward earnings against a peer median of 25.1× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points below its cost of capital (6.8% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$15.2B | HK$14.5B | HK$14.2B | HK$14.6B | HK$16.0B |
| Revenue growth | — | +2% | -3% | -9% | — |
| Gross profit | HK$6.67B | HK$6.60B | HK$6.82B | HK$7.04B | HK$8.20B |
| EBITDA | HK$3.20B | HK$3.10B | HK$3.59B | HK$3.50B | HK$4.56B |
| Net income | HK$1.54B | HK$1.75B | HK$2.24B | HK$2.21B | HK$3.21B |
| Free cash flow | n/a | HK$1.99B | HK$2.17B | HK$2.04B | HK$1.42B |
| Capital expenditure | n/a | HK$903M | HK$702M | HK$758M | HK$1.30B |
| Total debt | n/a | HK$6.59B | HK$5.45B | HK$5.26B | HK$5.36B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Weigao Group Medical Polymer 1066.HK | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| MicroPort Scientific 0853.HK | n/a | -45% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1066.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.2% | -4.4% | 10th lowest of 21 |
| 6-month return | -7.7% | +3.5% | 8th lowest of 20 |
| Distance from 52-week high | -45.5% | -21.0% | 5th lowest of 21 |
| Revenue growth (TTM) | +7.5% | +14.5% | 7th lowest of 21 |
| Operating margin | 13.6% | 14.6% | 10th lowest of 21 |
| Forward P/E | 8.2× | 25.1× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -12.6% | 13.2% | least demanding of 15 |
| Growth delivered (Del g) | +2.1% | +13.5% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | -14.8 pp | -4.8 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | -0.6 pp | +2.2 pp | 9th lowest of 21 |
| EV / EBITDA | 3.7× | 17.9× | cheapest of 16 |
| Net debt / EBITDA | -1.5× | -0.8× | 6th least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |